Pharmacological Therapy

  • John Weaver
  • Paul Austin
Part of the Urodynamics, Neurourology and Pelvic Floor Dysfunctions book series (UNPFD)


Urologists utilize clinical history, elimination diaries, noninvasive urodynamics, and conventional urodynamics to help gain an understanding of each patient’s unique bladder characteristics. It is from this information that urologists can determine whether implementing pharmacologic therapy will benefit a patient; furthermore, this information helps the physician tailor the correct pharmacotherapy to each patient based on their individual bladder physiology. Figure 28.1 shows a treatment algorithm which includes the optimal time to initiate pharmacotherapy for two common urologic issues: frequency and incontinence. There is a multitude of pharmacotherapy agents in an urologist’s armamentarium, and having an in-depth understanding of each agent is key in helping to determine the correct drug needed for each clinical scenario.


  1. 1.
    Finney SM, Andersson KE, Gillespie JI, et al. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int. 2006;98:503–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Nijman RJ. Role of antimuscarinics in the treatment of nonneurogenic daytime urinary incontinence in children. Urology. 2004;63:45–50.CrossRefPubMedGoogle Scholar
  3. 3.
    Austin PF, Vricella GJ. Functional disorders of lower urinary tract in children. In: Campbell-walsh urology tenth edition. Part XV Pediatric urology. 2012. pp. 3297–316.Google Scholar
  4. 4.
    Austin PF, Franco I. Chapter 15: Pharmacotherapy of the child with functional incontinence retention. In:Pediatric incontinence: evaluation and clinical management. Chichester: John Wiley and Sons, Ltd; 2015. Scholar
  5. 5.
    Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, et al. Pharmacological treatment of overactive bladder: report from the international consultation on incontinence. Curr Opin Urol. 2009;19(4):380–94.CrossRefPubMedGoogle Scholar
  6. 6.
    Sommer BR, O’Hara R, Askari N, et al. The effect of oxybutynin treatment on cognition in children with diurnal incontinence. J Urol. 2005;173:2125–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Veenboer PW, Huisman J, Chrzan RJ. Behavioral effects of long-term antimuscarinic use in patients with spinal dysraphism: a case control study. J Urol. 2013;190:2228–32.CrossRefPubMedGoogle Scholar
  8. 8.
    Youdim K, Kogan BA. Preliminary study of the safety and efficacy of extended-release oxybutynin in children. Urology. 2002;59:428–32.CrossRefPubMedGoogle Scholar
  9. 9.
    Gillespie JI, Palea S, Guilloteau V, Guerard M, Lluel P, Korstanje C. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the beta(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction. BJU Int. 2012;110(2 Pt 2):E132–42.CrossRefPubMedGoogle Scholar
  10. 10.
    Reddy PP, Borgstein NG, Nijman RJ, Ellsworth PI. Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity. J Pediatr Urol. 2008;4(6):428–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Ayan S, Kaya K, Topsakal K, Kilicarslan H, Gokce G, Gultekin Y. Efficacy of tolterodine as a first-line treatment for non-neurogenic voiding dysfunction in children. BJU Int. 2005;96(3):411–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Ek A. Adrenergic innervation and adrenergic mechanisms: a study of the human urethra. Acta Pharmacol Toxicol (Copenh). 1978;43:35–40.CrossRefGoogle Scholar
  13. 13.
    Krane RJ, Olsson CA. Phenoxybenzamine in neurogenic bladder dysfunction. II. Clinical considerations. J Urol. 1973;110(6):653–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Austin PF, Homsy YL, Masel JL, Cain MP, Casale AJ, Rink RC. Alpha-adrenergic blockade in children with neuropathic and nonneuropathic voiding dysfunction. J Urol. 1999;162(3 Pt 2):1064–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Homsy Y, Arnold P, Zhang W. Phase IIb/III dose ranging study of tamsulosin as treatment for children with neuropathic bladder. J Urol. 2011;186(5):2033–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Schulte-Baukloh H, Michael T, Miller K, Knispel HH. Alfuzosin in the treatment of high leak-point pressure in children with neurogenic bladder. BJU Int. 2002;90(7):716–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Cain MP, Wu SD, Austin PF, et al. Alpha blocker therapy for children with dysfunctional voiding and urinary retention. J Urol. 2003;170:1514–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Franco I, Cagliostro S, Collett T, Reda E. The use of alpha blockers to treat urgency/frequency syndrome in children. San Francisco, CA: American Acadamey of Pediatrics Meeting; 2007.Google Scholar
  19. 19.
    Ishihama H, Momota Y, Yanase H, Wang X, de Groat WC, Kawatani M. Activation of alpha1D adrenergic receptors in the rat urothelium facilitates the micturition reflex. J Urol. 2006;175(1):358–64.CrossRefGoogle Scholar
  20. 20.
    Somogyi GT, Tanowitz M, de Groat WC. Prejunctional facilitatory alpha 1-adrenoceptors in the rat urinary bladder. Br J Pharmacol. 1995;114(8):1710–6.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Szell EA, Yamamoto T, de Groat WC, Somogyi GT. Smooth muscle and parasympathetic nerve terminals in the rat urinary bladder have different subtypes of alpha(1) adrenoceptors. Br J Pharmacol. 2000;130(7):1685–91.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003;169(6):2253–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Van Batavia JP, Combs AJ, Horowitz M, et al. Primary bladder neck dysfunction in children and adolescents III: results of long-term alpha-blocker therapy. J Urol. 2010;183:724–30.CrossRefPubMedGoogle Scholar
  24. 24.
    Van Batavia JP, Combs AJ, Hyun G, et al. Simplifying the diagnosis of 4 common voiding conditions using uroflow/electromyography, electromyography lag time and voiding history. J Urol. 2011;186(Suppl. 4):1721–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Andersson KE, Martin N, Nitti V. Selective beta(3)-adrenoceptor agonists for the treatment of overactive bladder. J Urol. 2013;190(4):1173–80.CrossRefPubMedGoogle Scholar
  26. 26.
    Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33(1):17–30.CrossRefPubMedGoogle Scholar
  27. 27.
    Yamaguchi O, Marui E, Kakizaki H, Homma Y, Igawa Y, Takeda M, et al. Phase III, randomised, double-blind, placebo-controlled study of the beta3 -adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014;113(6):951–60.CrossRefPubMedGoogle Scholar
  28. 28.
    Austin PF, Bauer SB. Chapter 27: Medical management of the neurogenic bladder. In:Pediatric incontinence; evaluation and clinical management. Chichester: John Wiley and Sons, Ltd; 2015. Scholar
  29. 29.
    Chase J, Austin PF, Hoebeke P, et al. The management of dysfunctional voiding in children: a report from the standardisation committee of the International children’s continence society. J Urol. 2010;183:1296–302.CrossRefPubMedGoogle Scholar
  30. 30.
    Thom M, Campigotto M, Vemulakonda V, et al. Management of lower urinary tract dysfunction: a stepwise approach. J Pediatr Urol. 2012;8:20–93.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Urologic SurgerySt. Louis Children’s Hospital, Washington University SchoolSt. LouisUSA

Personalised recommendations